Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders

Nourhan I. Hussein; Andrea H. Molina; Gemalene M. Sunga; Moran Amit; Yu Leo Lei; Xiao Zhao; Jeffrey D. Hartgerink; Andrew G. Sikora; Simon Young

doi:10.1016/j.oraloncology.2024.106986

Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders

Nourhan I. Hussein
, Andrea H. Molina
, Gemalene M. Sunga
, Moran Amit
, Yu Leo Lei
, Xiao Zhao
, Jeffrey D. Hartgerink
, Andrew G. Sikora
, Simon Young

Head & Neck Surgery

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Immunotherapy has developed into an important modality of modern cancer treatment. Unfortunately, checkpoint inhibitor immunotherapies are currently delivered systemically and require frequent administration, which can result in toxicity and severe, sometimes fatal, adverse events. Localized delivery of immunomodulators for oral cancer and oral potentially malignant disorders offers the promise of maximum therapeutic potential and reduced systemic adverse effects. This review will discuss the limitations of current standard-of-care systemic therapies and highlight research advances in localized, intratumoral delivery platforms for immunotherapy for oral cancer and oral potentially malignant disorders.

Original language	English (US)
Article number	106986
Journal	Oral Oncology
Volume	158
DOIs	https://doi.org/10.1016/j.oraloncology.2024.106986
State	Published - Nov 2024

Keywords

Biomaterials
Cancer
Immunotherapy
Oral cancer
Oral potentially malignant disorders
Oral squamous cell carcinoma

ASJC Scopus subject areas

Oral Surgery
Oncology
Cancer Research

Access to Document

10.1016/j.oraloncology.2024.106986

Cite this

@article{5db1a0ba684541e79ba8b63e7f4acdbd,

title = "Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders",

abstract = "Immunotherapy has developed into an important modality of modern cancer treatment. Unfortunately, checkpoint inhibitor immunotherapies are currently delivered systemically and require frequent administration, which can result in toxicity and severe, sometimes fatal, adverse events. Localized delivery of immunomodulators for oral cancer and oral potentially malignant disorders offers the promise of maximum therapeutic potential and reduced systemic adverse effects. This review will discuss the limitations of current standard-of-care systemic therapies and highlight research advances in localized, intratumoral delivery platforms for immunotherapy for oral cancer and oral potentially malignant disorders.",

keywords = "Biomaterials, Cancer, Immunotherapy, Oral cancer, Oral potentially malignant disorders, Oral squamous cell carcinoma",

author = "Hussein, \{Nourhan I.\} and Molina, \{Andrea H.\} and Sunga, \{Gemalene M.\} and Moran Amit and Lei, \{Yu Leo\} and Xiao Zhao and Hartgerink, \{Jeffrey D.\} and Sikora, \{Andrew G.\} and Simon Young",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = nov,

doi = "10.1016/j.oraloncology.2024.106986",

language = "English (US)",

volume = "158",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders

AU - Hussein, Nourhan I.

AU - Molina, Andrea H.

AU - Sunga, Gemalene M.

AU - Amit, Moran

AU - Lei, Yu Leo

AU - Zhao, Xiao

AU - Hartgerink, Jeffrey D.

AU - Sikora, Andrew G.

AU - Young, Simon

PY - 2024/11

Y1 - 2024/11

N2 - Immunotherapy has developed into an important modality of modern cancer treatment. Unfortunately, checkpoint inhibitor immunotherapies are currently delivered systemically and require frequent administration, which can result in toxicity and severe, sometimes fatal, adverse events. Localized delivery of immunomodulators for oral cancer and oral potentially malignant disorders offers the promise of maximum therapeutic potential and reduced systemic adverse effects. This review will discuss the limitations of current standard-of-care systemic therapies and highlight research advances in localized, intratumoral delivery platforms for immunotherapy for oral cancer and oral potentially malignant disorders.

AB - Immunotherapy has developed into an important modality of modern cancer treatment. Unfortunately, checkpoint inhibitor immunotherapies are currently delivered systemically and require frequent administration, which can result in toxicity and severe, sometimes fatal, adverse events. Localized delivery of immunomodulators for oral cancer and oral potentially malignant disorders offers the promise of maximum therapeutic potential and reduced systemic adverse effects. This review will discuss the limitations of current standard-of-care systemic therapies and highlight research advances in localized, intratumoral delivery platforms for immunotherapy for oral cancer and oral potentially malignant disorders.

KW - Biomaterials

KW - Cancer

KW - Immunotherapy

KW - Oral cancer

KW - Oral potentially malignant disorders

KW - Oral squamous cell carcinoma

UR - https://www.scopus.com/pages/publications/85201122056

UR - https://www.scopus.com/pages/publications/85201122056#tab=citedBy

U2 - 10.1016/j.oraloncology.2024.106986

DO - 10.1016/j.oraloncology.2024.106986

M3 - Review article

C2 - 39137489

AN - SCOPUS:85201122056

SN - 1368-8375

VL - 158

JO - Oral Oncology

JF - Oral Oncology

M1 - 106986

ER -

Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this